SkinHealth Systems Inc. filings document the regulatory record for a Nasdaq-listed medical aesthetics company formerly known as The Beauty Health Company. The filings identify its Class A common stock, operating and financial results, non-GAAP reconciliations, and material-event disclosures tied to quarterly and annual reporting.
Its SEC record also includes proxy materials for annual stockholder voting, board and committee governance, director appointments, officer departures, compensatory arrangements, capital-structure disclosures and shareholder voting matters. These filings provide the formal disclosure framework for the company behind Hydrafacial, SkinStylus and related professional skin-health offerings.
SkinHealth Systems Inc. (SKIN) President and CEO Pedro Bruno Ferreira Malha had 99,742 and 78,045 shares of Class A Common Stock withheld on October 9, 2026, to satisfy tax withholding requirements on vesting of restricted stock units. Each entry lists $0.55 per share. The withheld shares do not represent a sale.
SkinHealth Systems Inc. repaid the remaining $103,235,000 aggregate principal amount of its 1.25% Convertible Senior Notes due 2026 on September 30, 2026, plus $645,218.75 in accrued and unpaid interest. The notes were set to mature on October 1, 2026.
The repayment satisfied and discharged the Indenture, and the trustee acknowledged that discharge. SkinHealth Systems Inc. was released from its remaining obligations under the Indenture except for provisions that survive by their terms.
SkinHealth Systems Inc. stockholders approved an amendment authorizing a reverse stock split of Class A common stock at a ratio from 1-for-5 through 1-for-20, with the exact ratio set by the board in its sole discretion. They also approved adjournment of the special meeting to a later date or dates, if necessary, to permit further proxy solicitation and voting if support for the split or shares present to establish a quorum were insufficient.
At the August 3, 2026 record date, 130,140,763 shares of Class A common stock were issued and outstanding. Holders of 115,893,322 shares, approximately 89.05% of eligible shares, were present virtually or represented by proxy at the September 22, 2026 meeting.
SkinHealth Systems Inc. (SKIN) announced that its Board of Directors has promoted Chief Financial Officer Michael Monahan to the role of Chief Financial and Operating Officer, effective September 3, 2026. In this expanded role, he now oversees all financial operations as well as the company’s supply chain, manufacturing, logistics, and customer experience functions.
In connection with the promotion, Mr. Monahan’s annual base salary will increase from $515,000 to $555,000, effective September 15, 2026. The company states there are no special arrangements or understandings leading to his appointment, no family relationships with directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
SkinHealth Systems Inc. reported that Sheri Lewis has decided to resign from her role as Chief Operations, Quality and Technology Officer to pursue other business opportunities outside the company. She notified the company on August 10, 2026, and will step down effective August 28, 2026.
The company states that Ms. Lewis’ resignation is not due to any disagreement with SkinHealth Systems, its board of directors, or management regarding operations, policies, or practices.
SkinHealth Systems Inc. Chief Financial Officer Michael P. Monahan reported a Form 4 transaction involving 32,357 shares of Class A Common Stock on 2026-08-10. The shares were withheld by the issuer to satisfy tax withholding requirements upon vesting of restricted stock units, and the disclosure states this does not represent a sale. Following this tax-withholding disposition, Monahan directly holds 1,955,280 shares of Class A Common Stock.
SkinHealth Systems Inc. is asking stockholders at a virtual special meeting on September 22, 2026 to approve a reverse stock split of its Class A common stock at a ratio between 1‑for‑5 and 1‑for‑20, to be chosen later by the board, and to approve potential adjournment of the meeting to solicit more votes if needed.
The main stated goal is to raise the share price to meet Nasdaq’s $1.00 minimum bid requirement after a May 2026 deficiency notice; the stock closed at $0.6610 on August 7, 2026 with 130,140,763 shares outstanding. The company warns that delisting could trigger “Fundamental Change” repurchase rights on its $103.2M 2026 convertible notes and $250.0M 2028 convertible notes, compared with $206.1M of cash, cash equivalents and restricted cash as of June 30, 2026, which could strain liquidity. The reverse split would reduce outstanding shares but leave authorized shares (including 300,000,000 Class A authorized) unchanged, increasing the number of shares available for future issuance and potential dilution.
SkinHealth Systems Inc. reported second quarter 2026 results with net sales of $72.1 million, a decrease of 7.8% from Q2 2025, as both delivery systems and consumables sales declined. The company sold 770 delivery systems, down from 957, while its active installed base grew to 36,516 systems.
Profitability metrics improved. Gross margin rose to 68.4% (adjusted 71.8%) from 62.8%, and operating expenses fell to $45.8 million from $51.8 million, reflecting lower personnel-related costs. SkinHealth posted a net loss of $2.7 million versus prior-year net income of $19.7 million, largely because Q2 2025 included an $18.1 million gain related to exchanges and repurchases of its 2026 notes. Adjusted EBITDA increased to $17.0 million, up from $13.9 million, with margin improving to 23.6%.
For the third quarter of 2026, management projects net sales of $65–$70 million and adjusted EBITDA of $5–$7 million. Full-year 2026 guidance calls for net sales of $280–$290 million and adjusted EBITDA of $39–$46 million. Cash, cash equivalents, and restricted cash totaled $206.1 million at June 30, 2026.
SkinHealth Systems Inc. is calling a virtual special stockholder meeting on September 22, 2026 to vote on a reverse stock split and a possible adjournment of the meeting. The reverse split would combine outstanding Class A common shares at a Board-selected ratio between 1-for-5 and 1-for-20, with authority for the Board to implement, delay or abandon it within one year.
The main stated objective is to raise the share price to meet Nasdaq Capital Market’s $1.00 minimum bid requirement after the stock closed at $0.6986 on July 28, 2026 and the company received a Nasdaq deficiency notice, with an initial compliance deadline of November 4, 2026. The filing explains that a Nasdaq delisting could trigger a “Fundamental Change” under its 1.25% 2026 and 7.95% 2028 convertible notes, potentially giving holders the right to demand cash repurchase of up to $353.2 million of principal, compared with $204.4 million of cash, cash equivalents and restricted cash reported as of March 31, 2026.
The reverse split would not change authorized share counts but would increase the number of authorized and unissued shares relative to shares outstanding, with potential dilution in future issuances. Fractional shares would be settled in cash. The Board unanimously recommends voting “FOR” both the reverse split and the adjournment proposal.